Observeship to the Latvian TB Supranational Reference Laboratory
19-22 of November, 2019
4 day observeship program on rapid molecular diagnostic methods for laboratory diagnostic of TB and drug susceptibility testing for new anti-TB drugs at the TB Supranational Reference Laboratory of Centre of TB and Lung Diseases for 1 participant from Uzbekistan.
Programmatic and clinical management of DR-TB in order to achieve the sustainable development goals
19- 28 of August, 2019
9 day intensive training for 18 participants – professionals from 5 countries Belarus, Ukraine, Moldova, Kyrgyzstan and Uzbekistan.
-
Programmatic and clinical management of DR-TB in order to achieve the sustainable developm
-
Programmatic and clinical management of DR-TB in order to achieve the sustainable developm
-
Programmatic and clinical management of DR-TB in order to achieve the sustainable developm
-
Programmatic and clinical management of DR-TB in order to achieve the sustainable developm
-
Programmatic and clinical management of DR-TB in order to achieve the sustainable developm
WHO CC Latvia`s 15h anniversary 19 of July, 2019
On 19 of July a meeting dedicated to the Latvian WHO Collaborating Centre for Research and Training in Management of Multidrug-Resistant Tuberculosis 15th anniversary took place in Riga. Over 15 years of work WHO CC has facilitated at least 200 comprehensive trainings, conferences and exchange of experience visits for nearly 3000 specialists from more than 60 countries. Currently WHO CC Latvia offers and runs more than 20 training programs for TB specialists, pediatricians, laboratory staff, surgeons, public health and TB control program representatives. WHO CC has been actively involving in different collaborative projects addressing the key challenges in TB control, as well as the research studies on implementation of the novel diagnostic tools, medicines, treatment regimens and conducted operation research to support the people-centered TB care implementation.We sincerely thank our colleagues and friends for support, trust and collaboration during these years!
Programmatic and clinical management of DR-TB in order to achieve the sustainable development goals3-12 of June, 2019
9-days course course in Russian for 8 specialists from Ukraine, Georgia and Kyrgyzstan
Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals
10-19 of September, 2018
33 participants from Uzbekistan, Tajikistan, Latvia, Lithuania, Kyrgyzstan, Kazakhstan and Georgia attended the 9-day WHO CC Latvia intensive course on "Programmatic and clinical management of drug-resistant tuberculosis in order to achieve sustainable development goals".
Advanced Training for Trainers of the ‘’Local centers of Excellence ‘’ (HUBs) in Ukraine, established by PATH and KNCV
9-18 of July, 2018
12 participants from Ukraine local centres of Excellence visited WHO CC Latvia to participate in practical training in building human resource capacity to establish sustainable model of centers of excellence in Ukraine. Objectives of the training was to promote their capacity and independent functioning, to support Centers of excellence in Ukraine to be able to effectively design, implement, coordinate and manage the training programs, competence-based training strategies, training curriculum to respond to the training needs of the target groups, as well as delivering the trainings in a learning environment conducive for training and ensuring follow-up and mentoring after the training.
Programmatic introduction of the new and re-purposed anti-TB medicines for treatment of DR-TB and Line Probe Assay technology - rapid molecular drug susceptibility test available for the diagnosis of DR-TB
28th of May - 1st of June, 2018
Two parallel 5-day trainings in Russian took place in Riga, WHO CC Latvia for 4 TB laboratory specialists from Kyrgyzstan on rapid molecular diagnostic methods for laboratory diagnostic of TB and drug susceptibility testing for new anti-TB drugs, and 11 TB clinicians from Latvian and Kyrgyzstan on new and re-purposed anti TB drugs use.